176 related articles for article (PubMed ID: 15745986)
1. Risks and benefits of phase 1 oncology trials, revisited.
Kurzrock R; Benjamin RS
N Engl J Med; 2005 Mar; 352(9):930-2. PubMed ID: 15745986
[No Abstract] [Full Text] [Related]
2. Phase 1 clinical trials in oncology.
Miller MJ
N Engl J Med; 2005 Jun; 352(23):2451-3; author reply 2451-3. PubMed ID: 15948270
[No Abstract] [Full Text] [Related]
3. Risks and benefits associated with novel phase 1 oncology trial designs.
Koyfman SA; Agrawal M; Garrett-Mayer E; Krohmal B; Wolf E; Emanuel EJ; Gross CP
Cancer; 2007 Sep; 110(5):1115-24. PubMed ID: 17628485
[TBL] [Abstract][Full Text] [Related]
4. [Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations].
Hanauske AR
Med Klin (Munich); 1996 Apr; 91 Suppl 3():68-70. PubMed ID: 8692122
[No Abstract] [Full Text] [Related]
5. "Therapeutic intent" in phase 1 oncology trials: a justifiable objective.
Markman M
Arch Intern Med; 2006 Jul; 166(14):1446-8. PubMed ID: 16864753
[No Abstract] [Full Text] [Related]
6. Phase 1 clinical trials in oncology.
Sekine I; Tamura T
N Engl J Med; 2005 Jun; 352(23):2451-3; author reply 2451-3. PubMed ID: 15948271
[No Abstract] [Full Text] [Related]
7. Choice of designs and doses for early phase trials.
Zhou Y
Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
[TBL] [Abstract][Full Text] [Related]
8. Risks and benefits of phase 1 oncology trials, 1991 through 2002.
Horstmann E; McCabe MS; Grochow L; Yamamoto S; Rubinstein L; Budd T; Shoemaker D; Emanuel EJ; Grady C
N Engl J Med; 2005 Mar; 352(9):895-904. PubMed ID: 15745980
[TBL] [Abstract][Full Text] [Related]
9. Dose selection in phase I studies: why we should always go for the most effective.
Haines IE
J Clin Oncol; 2008 Jul; 26(21):3650-2; author reply 3652-3. PubMed ID: 18640947
[No Abstract] [Full Text] [Related]
10. Dose selection in phase I studies: why we should always go for the top.
Sleijfer S; Wiemer E
J Clin Oncol; 2008 Apr; 26(10):1576-8. PubMed ID: 18332465
[No Abstract] [Full Text] [Related]
11. Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?
Miller FG; Joffe S
Clin Trials; 2008; 5(6):617-23. PubMed ID: 19029210
[TBL] [Abstract][Full Text] [Related]
12. Descriptions of benefits and risks in consent forms for phase 1 oncology trials.
Horng S; Emanuel EJ; Wilfond B; Rackoff J; Martz K; Grady C
N Engl J Med; 2002 Dec; 347(26):2134-40. PubMed ID: 12501226
[TBL] [Abstract][Full Text] [Related]
13. [A combination phase I/II study--dose escalation plan].
Yamamoto N
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2267-74. PubMed ID: 11142175
[TBL] [Abstract][Full Text] [Related]
14. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
15. Comment regarding benefit in phase 1 oncology trials.
Morse M
Clin Trials; 2008; 5(6):626; discussion 630. PubMed ID: 19029212
[No Abstract] [Full Text] [Related]
16. [Pharmacokinetically guided dose-escalation (PGDE) strategy].
Saeki T
Gan To Kagaku Ryoho; 2000 Jul; 27(7):1069-74. PubMed ID: 10925698
[TBL] [Abstract][Full Text] [Related]
17. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
18. Discrete event simulation applied to pediatric phase I oncology designs.
Barrett J; Skolnik J; Jayaraman B; Patel D; Adamson P
Clin Pharmacol Ther; 2008 Dec; 84(6):729-33. PubMed ID: 18923388
[No Abstract] [Full Text] [Related]
19. Health care disparity: an overlooked problem in phase I oncology trials.
O'Brien TE
J Clin Oncol; 2007 Jul; 25(21):3182-3. PubMed ID: 17634502
[No Abstract] [Full Text] [Related]
20. Evaluation of fixed dosing of new anticancer agents in phase I studies.
Levêque D
Anticancer Res; 2008; 28(5B):3075-7. PubMed ID: 19031959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
